Haleon PLC closed 6.80% below its 52-week high of £4.18, which the company reached on March 4th.
British consumer healthcare group Haleon on Thursday said 2025 revenue and profit growth would be weighted to the second half of the year, overshadowing a strong end to 2024 and sending its shares ...
Consumer healthcare giant Haleon has reported a strong financial performance for 2024, with organic revenue growth of five per cent. However, revenue declined by 0.6 per cent on a reported basis to ...
Haleon CEO Brian McNamara says his company is not as exposed as peers to tariff risks, as the consumer healthcare company ...
Haleon's dividend grew 10% and is well-covered by FCF, but the 1.6% yield is less attractive compared to peers. See why I ...
Hsbc Global Res lowered shares of Haleon (NYSE:HLN – Free Report) from a strong-buy rating to a hold rating in a research ...
Haleon Pakistan Limited has announced its first international shipment of locally manufactured Centrum multivitamins to Kenya ...
Haleon is one of the largest consumer healthcare companies in the world. Over the last few years, Haleon has achieved a more rationalized operation by divesting multiple non-strategic brands ...
HSBC analyst Jeremy Fialko downgraded Haleon (HLN) to Hold from Buy with a 420 GBp price target Discover the Best Stocks and Maximize Your ...
Haleon had a net margin of 10.85% and a return on equity of 14.76%. The company had revenue of $3.54 billion during the quarter, compared to analysts’ expectations of $3.38 billion.
Haleon plc (NYSE: HLN) Q4 2024 Earnings Call Transcript February 27, 2025 Haleon plc misses on earnings expectations.
Berenberg analyst Bethan Davies raised the firm’s price target on Haleon (HLN) to 457 GBp from 456 GBp and keeps a Buy rating on the shares. See what stocks are receiving Strong Buy ratings from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results